Diligence memo · auto-generated · as of July 2, 2026
Sunflower Therapeutics, PBC
Sunflower Therapeutics, PBC looks fair against its niche peers and is quiet on financing cadence.
Businessfiled
Sunflower Therapeutics, PBC operates in Biotechnology, based in Hingham.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Sunflower Therapeutics, PBC has raised $2.6M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $2.0M on 2024-05-13.
Most recent recorded round closed around 2024-05-13.
Valuation (modeled)modeled
Provath models Sunflower Therapeutics, PBC at approximately $11M (range $1.5M–$29M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.74× the median modeled value of Seed Biotechnology companies in 2022–2024 (207 peers) — value vs value, same stage and era. Within the normal band (74% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 19 months.
Last raise 2.1 yr ago; this sector typically re-raises about every 14 months.
Slightly overdue versus sector cadence.
The last round stepped up 3.3× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 32% of Biotechnology peers (4293 compared).
Modeled value ranks above 19% of those peers.
Closest niche peers: Mesentech Inc., Marlinspike Therapeutics, Inc., Microbial Machines, Inc., Pearl Diagnostics, Inc., Crossfire Medical Inc.
Peoplefiled
5 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.